treatment of melanoma patients
context of melanoma Melanoma
TRIB2-mediated resistance
melanoma therapy
established treatment of metastatic melanoma
treatment modalities
TRIB2-mediated drug resistance
specific treatment options
co-treatment strategies
MEK inhibitors
protein TRIB2
novel mechanism of resistance
MEK inhibitiors
clinical trials
BRAF inhibitors
clinical relevance
mutated BRAF
predictive biomarker
broad spectrum of drugs
aggressive form of skin cancer resistant
DTIC
dacarbazine
administration
dabrafenib
use
standard therapies
AKT
mTOR
PI3K
vemurafenib
kinase
prognostic
response rates
host lab
trametinib
mechanisms
expected results
effects
effectiveness
project